<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04752709</url>
  </required_header>
  <id_info>
    <org_study_id>TR-1155</org_study_id>
    <nct_id>NCT04752709</nct_id>
  </id_info>
  <brief_title>Efficacy of Surface Electrical Stimulation for Urge Urinary Incontinence in Women</brief_title>
  <official_title>Clinical Study to Evaluate the Efficacy of Surface Electrical Stimulation for Urge Urinary Incontinence in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elidah, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elidah, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to evaluate the effectiveness of the ELITONE-UUI electrical&#xD;
      muscle stimulation device on treating urge incontinence. The aim of the device is to&#xD;
      stimulate the pelvic floor muscles and surrounding structures to improve urinary&#xD;
      incontinence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research is to evaluate the effectiveness of the ELITONE-UUI electrical&#xD;
      muscle stimulation device on treating urge incontinence in women. The aim of the device is to&#xD;
      stimulate the pelvic floor muscles and surrounding structures to improve urinary&#xD;
      incontinence. This is a randomized prospective controlled study of two active groups with a&#xD;
      stimulation frequency difference between the groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized between two active groups</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Device looks identical. A third person masks which software is coded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy assessed by average number of urinary incontinence episodes per day</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by number of serious adverse events</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by change in Incontinence quality of life questionnaire (I-QOL)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by reduction in average Pads used per day</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by reduction in average bathroom visits</measure>
    <time_frame>6 weeks</time_frame>
    <description>Day and night distinction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by reduction in average urge incontinence episodes</measure>
    <time_frame>6 weeks</time_frame>
    <description>Distinction with and without leaking</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Urge Incontinence</condition>
  <arm_group>
    <arm_group_label>Active Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region, with stimulation group A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region with stimulation group B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ELITONE UUI</intervention_name>
    <description>External electrical stimulation</description>
    <arm_group_label>Active Group A</arm_group_label>
    <arm_group_label>Active Group B</arm_group_label>
    <other_name>ELITONE muscle stimulator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Predominant urge urinary incontinence as determined by responses to a series of three&#xD;
             standard questions from the King's Health Questionnaire; specifically:&#xD;
&#xD;
               -  An affirmative response to &quot;Is it very difficult to control when you have a&#xD;
                  strong urge to urinate?&quot;,&#xD;
&#xD;
               -  An affirmative or negative response to &quot;Do you lose urine with physical&#xD;
                  activities such as coughing, sneezing, running?&quot;,&#xD;
&#xD;
               -  And, if an affirmative response to the second question, an affirmative response&#xD;
                  to &quot;Are more of your incontinence episodes due to a strong urge to urinate than&#xD;
                  to abdominal pressure such as sneezing?&quot;&#xD;
&#xD;
          -  Mild-moderate incontinence symptoms as determined by self-reported typical number of&#xD;
             accidents of 1 or more per 24 hours. Symptom severity is later verified with data from&#xD;
             the Daily Log (See 5.4)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 1 incontinence accident (leak) per day*&#xD;
&#xD;
          -  Severe incontinence as determined by self-reported &gt;5 accidents per day&#xD;
&#xD;
          -  Currently pregnant, may be pregnant, attempting to become pregnant, or delivery within&#xD;
             previous 6 weeks&#xD;
&#xD;
          -  Vaginal or pelvic surgery within previous 6 months&#xD;
&#xD;
          -  Severe Obesity as defined by BMI &gt;= 35&#xD;
&#xD;
          -  Change in incontinence medication type or dosing within the last 3 months.&#xD;
&#xD;
          -  History or symptoms of urinary retention, extra-urethral incontinence, overflow&#xD;
             incontinence&#xD;
&#xD;
          -  Pelvic pain/painful bladder syndrome&#xD;
&#xD;
          -  Active urinary tract infection (UTI) or history of recurrent UTIs (more than three in&#xD;
             a year), or recurrent vaginitis (bacterial/fungal)&#xD;
&#xD;
          -  Tissues protruding outside the vagina at rest&#xD;
&#xD;
          -  Presence of incontinence-associated dermatitis or other perineal skin disorders or&#xD;
             lesions,&#xD;
&#xD;
          -  Complete denervation of the pelvic floor&#xD;
&#xD;
          -  Conductive inter-uterine devise (IUD/Coil) or metal implants in the abdominal or&#xD;
             pelvic area, including the hip and lumbar spine,&#xD;
&#xD;
          -  Chronic coughing&#xD;
&#xD;
          -  Previous use of Interstim device or Botox for UI&#xD;
&#xD;
          -  Implanted cardiac device, untreated cardiac arrhythmia or suffer from other heart&#xD;
             problems.&#xD;
&#xD;
          -  Cancer, epilepsy or cognitive dysfunction&#xD;
&#xD;
          -  Underlying neurologic/neuromuscular disorder&#xD;
&#xD;
          -  Impaired decision making, suicidal thoughts, or drug/alcohol dependence&#xD;
&#xD;
          -  Lacks capacity to consent for themselves.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gloria Kolb, M.S.</last_name>
    <role>Study Director</role>
    <affiliation>Elidah, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gloria Kolb, M.S.</last_name>
    <phone>203-304-9414</phone>
    <email>director@elitonestudy.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Elidah</name>
      <address>
        <city>Monroe</city>
        <state>Connecticut</state>
        <zip>06468</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Kolb, M.S.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>incontinence</keyword>
  <keyword>bladder</keyword>
  <keyword>urge</keyword>
  <keyword>urgency</keyword>
  <keyword>stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

